



# HEALTH INFORMATION *designs*



**West Virginia  
Department of Health and Human  
Resources**

**Bureau for Medical Services  
Drug Utilization Review Board**

February 24, 2016

# Fourth Quarter 2015

- **Profiles Reviewed** **1,900**
- **Cases Identified** **1,641**
- **Letters Mailed**
  - **Prescribers** **1,974**
  - **Pharmacies** **1,770**
- **Responses**
  - **Prescribers** **268** **14.0%**
    - **Oct.: 155 (37%) / Nov.: 101 (17%) / Dec.: 12 (1%)**
  - **Pharmacies** **122** **7.0%**
    - **Oct.: 53 (14%) / Nov.: 65 (15%) / Dec.: 4 (0%)**



# Fourth Quarter 2015

- **Benzodiazepines/clozapine**
- **Benzodiazepines anxiolytics/buspirone**
- **Methadone/CNS depressants**
- **Butrans<sup>®</sup>/skeletal muscle relaxants**
- **SSRIs/tramadol**
- **Tramadol/cyclobenzaprine**
- **Tramadol/opioid type analgesics**
- **Tramadol/seizures**
- **Bupropion and alcohol dependence**
- **Bupropion and drugs that lower seizure threshold**
- **Bupropion nonadherence**
- **Controlled substances**



# Fourth Quarter 2015

## Distribution of Cases

- **Drug–Disease Interactions: 6.4%**
  - Patients receiving a drug that may worsen or precipitate a medical condition.
- **Drug–Drug Conflict: 34.9%**
  - Patients receiving 2 or more drugs that may interact and produce unpredictable and undesirable effects.
- **Overutilization: 13.9%**
  - Patients taking medications in apparently excessive doses or for excessive lengths of time.
- **Non-compliance: 5.5%**
  - Patients not taking medication according to directions, resulting in possible sub-therapeutic response.
- **Clinical Appropriateness: 39.3%**
  - Patients who are taking medications for treatment of a disease for which the medication is not standard of care.



# Fourth Quarter 2015

## Evaluation

- **Extremely useful**      **27**
- **Useful**                      **65**
- **Somewhat useful**      **24**
- **Neutral**                      **43**
- **Not useful**                **32**



# Top Drugs by Dollars 2015

Drug	Prescription Count	Dollars
Lantus® SoloSTAR®	19,857	\$9.6 million
Spiriva® HandiHaler®	25,324	\$7.7 million
NovoLog® FlexPen®	13,032	\$6.4 million
Advair 250/50 Diskus®	16,673	\$4.9 million
Symbicort® 160/4.5	17,775	\$4.8 million
Harvoni®	165	\$4.7 million
Suboxone® 8/2 film	37,196	\$4.6 million
Suboxone® (all others)	1,782	< \$140,000



# Addition of Suboxone Patients to Lock-In Program

Stats 2015	Lock-In Patients	Letters Sent	Total Calls
May	871	152	193
June	1,548	289	292
July	2,165	1,399	368
August	2,986	909	287
September	3,437	670	232
October	3,466	155	117
November	3,456	134	80
December	3,457	123	97



# Fourth Quarter 2015

- Educational Interventions:
  - Atypical neuroleptics (pediatric patients)
    - 366 physician letters
  - Auvi-Q<sup>®</sup> recall notification letters
    - 851 letters
  - Incretin mimetics non-preferred notification letters
    - 1,119 letters



---

*Questions?*

